Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • Data Center
    • Data Center Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Government
January 23, 2017 12:00 AM

Trump kills trade deal that would have benefited pharma and potentially raised drug costs

Adam Rubenfire
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    The Trans-Pacific Partnership's effects on drug prices and patents alarmed some physician-advocates. Above, representatives from the U.S. and Peru met in Washington in April 2015 to discuss trade issues related to the pact.

    (Story updated January 24, 2017)

    President Donald Trump has signed an order withdrawing the U.S. from the Trans-Pacific Partnership that has been contested by both healthcare companies and activists.

    President Barack Obama had ended negotiations on the deal, which extends greater protection for pharmaceutical patents across a dozen Pacific Rim countries. Obama, however, failed to garner enough support in Congress to ratify its passage into law. Trump had pledged during his campaign to remove the U.S. from the partnership, which he called a “horrible deal.” It was also criticized by the Democratic presidential candidate Hillary Clinton.

    The deal was never about “free trade,” but rather about protecting the interests of brand-name pharmaceutical companies, said Peter Maybarduk, director of Public Citizen's Access to Medicines Program. Moving forward, the Trump administration should encourage competition in the sector, he said.

    It would have eliminated 18,000 taxes that other countries place on goods from the U.S. The nations that have signed the TPP are the U.S., Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore and Vietnam. But the agreement had few steadfast fans, as activists feared its intellectual property protections would increase global pharmaceutical prices, while the industry felt those protections didn't go far enough.

    Both consumer group Public Citizen and aid organization Doctors Without Borders decried the deal's intellectual property provisions that required participating countries to extend data protection for biologic medicines—drugs produced with living matter—for at least five to eight years. They argued that doing so would keep biosimilars—the reproduced “generic” versions of biologics—from entering the market and bringing prices down.

    Pharmaceutical Research and Manufacturers of America, which represents the U.S. drug industry, was concerned that the intellectual property protections weren't strong enough. Drugmakers supported 12 years of data exclusivity to match the period required under U.S. federal law. Some of the countries in the deal don't have any exclusivity laws for biologics.

    “PhRMA is supportive of bilateral and multilateral free trade agreements that include strong intellectual property protections, enhance market access and help us deliver lifesaving medicines to the world’s patients,” said Stephen Ubl, the lobby’s CEO. “As the incoming administration and Congress prepare to shape our trade agenda, we look forward to working with our government’s leadership to secure smart, fair trade agreements that open new markets and help grow our economy and create better, higher-paying jobs.”

    The Advanced Medical Technology Association, known as AdvaMed, has been supportive of the deal, saying early last year that the deal would combat “corrupt business practices” and establish global “codes of conduct” for device trade. AdvaMed did acknowledge, however, that certain issues and concerns raised by other business sectors and Congress needed to be solved.

    AdvaMed offered a short, forward-looking statement on Monday following Trump's order.

    “The medical technology industry has consistently supported trade agreements that open markets and improve patient access to needed medical advancements. We look forward to working with the new administration as it pursues these pro-innovation, pro-patient goals,” said Ralph Ives, AdvaMed's executive vice president of global strategy and analysis.

    “I think the Trump administration should use its power under existing law to make it clear we will allow generic competition,” Public Citizen's Maybarduk said. “They should work with legislators, and legislators should push for a comprehensive agenda on drug pricing, recognizing that monopoly power is the core of the problem.”

    The Generic Pharmaceutical Association said in a statement Tuesday that policymakers should develop patent rules that balances incentives for innovation with a desire for generic competition.. GPhA also called on the Trump administration and Congress to stop brand drug companies from interfering in generic drug development and access.

    “Increasing competition from generic drugs and biosimilars is a proven way to lower health spending,” GPhA said. “We look forward to working with the Trump administration, bipartisan members of Congress and others on policies that encourages access to more affordable medicines in the United States and around the world.”

    Judit Rius Sanjuan, the U.S. manager for Doctors Without Borders' Access Campaign, said her organization believes it's possible to enact a future trade agreement that satisfies both the private sector and NGOs that are concerned about drugmaker monopolies. “We would like to see an agreement that is a win-win for innovation and access,” she said.

    But Sanjuan said it's too early to know what the Trump administration's next steps will be, and it's hard to tell how the White House will treat the interests of pharmaceutical companies and NGOs. While the Republican party tends to be pro-industry, Trump chastised the pharmaceutical industry's pricing practices at many points throughout his campaign. He has also said that he supports importing drugs from other countries and allowing Medicare to directly negotiate on drug prices, which are both measures that are opposed by PhRMA.

    Early in his campaign, Trump called the TPP a “horrible deal … designed for China to come in, as they always do, through the back door and totally take advantage of everyone.” China isn't involved in the partnership; in fact, it's possible that China could swoop in with its own deal to entice Pacific Rim countries.

    Sen. John McCain (R-Ariz.), chairman of the Senate Armed Services Committee and a former presidential candidate, said in a statement that withdrawing from the TPP was a “serious mistake” that would have lasting consequences for the U.S. economy and its position in the Asia-Pacific region.

    “This decision will forfeit the opportunity to promote American exports, reduce trade barriers, open new markets, and protect American invention and innovation,” McCain said. “It will create an opening for China to rewrite the economic rules of the road at the expense of American workers.”

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    abortion-pill-misoprostol-legal
    Abortion pill case advances to appeals court, on course to Supreme Court
    young doctor medical resident
    Federal physician recruitment program at risk
    Most Popular
    1
    More healthcare organizations at risk of credit default, Moody's says
    2
    Centene fills out senior executive team with new president, COO
    3
    SCAN, CareOregon plan to merge into the HealthRight Group
    4
    Blue Cross Blue Shield of Michigan unveils big push that lets physicians take on risk, reap rewards
    5
    Bright Health weighs reverse stock split as delisting looms
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • Data Center
      • Data Center Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing